|
| 36728679 | Prevalence and Impact of Obesity in a Population-Based Cohort of Patients With Crohn's Disease. | J Clin Gastroenterol | 2024 |
| 38010661 | Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. | Aliment Pharmacol Ther | 2024 |
| 37942921 | Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme. | J Crohns Colitis | 2024 |
| 37821035 | Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis. | Clin Gastroenterol Hepatol | 2024 |
| 37279944 | Characteristics, Clinical Outcomes, and Prognosis of Anal and Pouch-related Carcinoma in Patients With Crohn's Disease. | Inflamm Bowel Dis | 2024 |
| 37071852 | Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease. | Inflamm Bowel Dis | 2024 |
| 36812365 | The Incidence of Pouch Neoplasia Following Ileal Pouch-Anal Anastomosis in Patients With Inflammatory Bowel Disease. | Inflamm Bowel Dis | 2024 |
| 34864789 | Outcomes of Fecal Microbiota Transplantation for C. difficile Infection in Inflammatory Bowel Disease : A Systematic Review and Meta-analysis. | J Clin Gastroenterol | 2023 |
| 37718932 | Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE. | Aliment Pharmacol Ther | 2023 |
| 37636008 | Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies. | Crohns Colitis 360 | 2023 |
| 37663925 | Economic Burden of Fatigue in Inflammatory Bowel Disease. | Crohns Colitis 360 | 2023 |
| 37507083 | Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays. | Clin Biochem | 2023 |
| 37683686 | Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study. | Lancet Gastroenterol Hepatol | 2023 |
| 37819733 | Home-based Biologic Infusions for Inflammatory Bowel Disease: Are We Ready for Prime Time? | Inflamm Bowel Dis | 2023 |
| 38095092 | Risankizumab to treat moderately to severely active Crohn's disease in adults: an evaluation of trials and data. | Expert Rev Gastroenterol Hepatol | 2023 |
| 37811776 | Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease. | Am J Gastroenterol | 2023 |
| 35792493 | Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program. | Inflamm Bowel Dis | 2023 |
| 35816130 | The Current State of Care for Black and Hispanic Inflammatory Bowel Disease Patients. | Inflamm Bowel Dis | 2023 |
| 37149812 | Adalimumab Therapeutic Drug Monitoring Improves Treatment Outcome in Patients with Psoriasis. | J Invest Dermatol | 2023 |
| 37308036 | Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study. | Clin Gastroenterol Hepatol | 2023 |
| 37004970 | Effectiveness of Hepatitis B Vaccination for Patients With Inflammatory Bowel and Celiac Disease. | Clin Gastroenterol Hepatol | 2023 |
| 37296268 | Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in Patients with Crohn's Disease and Ulcerative Colitis. | Pharmacoecon Open | 2023 |
| 37356426 | Anemia and Systemic Inflammatory Markers in Patients with Perianal Disease: Hidradenitis Suppurativa and Inflammatory Bowel Disease. | Dermatology | 2023 |
| 37224198 | Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. | N Engl J Med | 2023 |
| 36402202 | Interobserver agreement of the modified Paris classification and histology prediction of colorectal lesions in patients with inflammatory bowel disease. | Gastrointest Endosc | 2023 |
| 36917429 | Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease. | Adv Ther | 2023 |
| 36474097 | Endoscopic Bariatric Therapies for the Management of Obesity in Patients with Inflammatory Bowel Disease. | Obes Surg | 2023 |
| 36645051 | Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results. | Inflamm Bowel Dis | 2023 |
| 36610500 | Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too Early to Conclude. | Clin Gastroenterol Hepatol | 2023 |
| 36871566 | The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. | Lancet Gastroenterol Hepatol | 2023 |
| 36464141 | Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment. | Clin Gastroenterol Hepatol | 2023 |
| 36075499 | Inflammatory Bowel Disease Is Associated With an Increased Risk of Incident Acute Arterial Events: Analysis of the United Kingdom Biobank. | Clin Gastroenterol Hepatol | 2023 |
| 36342120 | Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. | Inflamm Bowel Dis | 2023 |
| 36149260 | Osteonecrosis in Inflammatory Bowel Disease: Clinical Features, Risk Factor Analysis, and Outcomes. | Inflamm Bowel Dis | 2023 |
| 36272109 | Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease. | J Crohns Colitis | 2023 |
| 36266762 | Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. | Aliment Pharmacol Ther | 2023 |
| 36191274 | The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium. | Am J Gastroenterol | 2023 |
| 36006011 | Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study. | J Crohns Colitis | 2023 |
| 36113491 | Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial. | Am J Gastroenterol | 2023 |
| 33039584 | Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. | Clin Gastroenterol Hepatol | 2022 |
| 35644166 | Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. | Lancet | 2022 |
| 35644154 | Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. | Lancet | 2022 |
| 35644155 | Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. | Lancet | 2022 |
| 35560533 | Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. | United European Gastroenterol J | 2022 |
| 36479863 | The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries. | United European Gastroenterol J | 2022 |
| 36474165 | Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis. | BMC Gastroenterol | 2022 |
| 36397817 | Novel Therapies for Patients With Inflammatory Bowel Disease. | Gastroenterol Hepatol (N Y) | 2022 |
| 36777041 | Clinical Course and Impact of Immune Checkpoint Inhibitor Colitis Resembling Microscopic Colitis. | Crohns Colitis 360 | 2022 |
| 36045902 | A Cohort Study of the Age at Menopause in Female Patients With and Without Inflammatory Bowel Disease. | Crohns Colitis 360 | 2022 |
| 35973143 | The Global Incidence of Peptic Ulcer Disease Is Decreasing Since the Turn of the 21st Century: A Study of the Organisation for Economic Co-Operation and Development (OECD). | Am J Gastroenterol | 2022 |